Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
-
2281
-
2282
-
2283
-
2284
-
2285
-
2286
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
2287
-
2288
CHAMPS pilot Hb dataset.
Published 2025“…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
-
2289
-
2290
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2291
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2292
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2293
-
2294
-
2295
-
2296
-
2297
-
2298
-
2299
-
2300